Abstract

Obesity has been growing at an alarm rate worldwide Several evidence highlights the role of obesity in the development cardiovascular risk and ischemic diseases. Visceral fat contributes to a systemic inflammatory state and circulating mediators of inflammation participate in the mechanisms of vascular damage in obese patients. Moreover, these inflammatory proteins cause insulin-resistance leading to FRC appearance and cardiovascular disease

This review shows how the obesity causes inflammatory state and insulin resistance enhancing cardiovascular risk.

Keywords: Obesity; Inflammation; Insulin-Resistance; Cardiovascular Risk

References

1. WHO: Obesity and overweight.
2. Walker GE., et al. “Obesity modifies expression profiles of metabolic markers in superficial and deep subcutaneous abdominal adipose tissue depots”. Endocrine (2014): 99-106.
3. Carcagnì A. “Obesity, inflammation and cardiovascular risk: the genesis of atheroma”. Outpatients Cardiology (2021): 31-42.
4. Karastergiou K., et al. “Sex differences in human adipose tissues - the biology of pear shape”. Biology of Sex Differences (2012): 3-13.
5. Andersen GF., et al. “Confronting Chronic Disease in Countries”. New England (2007): 209-2011.
6. Berg AH., et al. “Adipose Tissue, Inflammation, and cardiovascular disease”. Circulation Research (2005): 939-949.
7. Pencina MJ., et al. “Predicting the 30-year risk of cardiovascular disease: the Framingham heart study”. Circulation (2009): 3078-3084.
8. Cottam DR., et al. “The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss”. Obesity Surgery (2004): 589-600.
9. Lomonaco R., et al. “Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease”. Hepatology (2012): 1389-1397.
10. Schaffler A., et al. “Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease”. Nature Clinical Practice Gastroenterology and Hepatology (2005): 273-280.
11. Bray GA., et al. “Clinical evaluation of the overweight patient”. Endocrine (2000): 167-186.
12. DeFronzo RA., et al. “Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease”. Diabetes Care (1991): 173-179.
13. Yu W and Ji-Dong Cheng. “Uric Acid and Cardiovascular Disease: An Update from Molecular Mechanism to Clinical Perspective”. Frontiers in Pharmacology (2020).
14. Yuri YS and Johnson RJ. “Uric Acid: the oxidant-antioxidant paradox”. NN Nucleic Acids (2008): 608-619.
15. Novo G., et al. “Impact of insulin resistance on cardiac and vascular function”. International Journal of Cardiology (2016): 1095-1099.
16. Reaven GM., et al. “Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system”. The New England Journal of Medicine (1996): 334-374.
17. Fuster V., et al. “Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts”. Journal of the American College of Cardiology (2005): 937-954.
18. Violi F., et al. “Role of NADPH oxidase in atherosclerosis”. Future Cardiology (2009): 83-92.

Citation

Citation: Carcagnì Addolorata. “Obesity and the Genesis of Cardiovascular Risk: A Review". Acta Scientific Cardiovascular System 1.7 (2022): 09-13.

Copyright

Copyright: © 2022 Carcagnì Addolorata. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.